Abbott Laboratories vs. Summit Therapeutics Inc. Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| ABT | SMMT | |
|---|---|---|
| Market Cap | $191.16 billion | $13.67 billion |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | $-856,089,000 |
ABT leads on 2 of 2 size & scale factors.
Valuation
| ABT | SMMT | |
|---|---|---|
| P/E Ratio | 35.21 | — |
| Price / Book | 3.69 | 21.69 |
| Price / Sales | 4.10 | — |
ABT leads on 1 of 1 valuation factors.
Profitability
| ABT | SMMT | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | -135.89% |
ABT leads on 1 of 1 profitability factors.
Dividend
| ABT | SMMT | |
|---|---|---|
| Dividend Yield | 2.32% | — |
| Payout Ratio | 81.55 | — |
ABT and SMMT split the dividend factors evenly.
Risk & Sentiment
| ABT | SMMT | |
|---|---|---|
| Short Interest | 0.57% | 0.00% |
SMMT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, SMMT overview, SMMT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.